OakChart

Immutep Limited ADR

IMMPHealthcare·Biotechnology·Australia·Nano·NASD·Nov 11 • 10:51 AM ET

3.47+0.01 (0.29%)
2026-11-11 16:53 CET
Market cap
25.50 USD m
Revenue, TTM
10.03 USD m
Net income, TTM
-53.59 USD m
Free cash flow, TTM
-39.03 USD m
EPS diluted, TTM
-7.28
P/E
-
Compare

Price

IMMP against its 20, 50 and 200-day averages
2050200miss
10.0020.0030.0080K160KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMMPclose 3.4720-day 3.2150-day 4.56200-day 14.833.47

95.1% under the 52-week high of 70.60 on 8 Dec 2025. 52-week low 2.66 on 5 Nov 2026. Last 15 sessions, 47.4% high to low

Profile

IMMP
52-week range, 1% of the way up
2.6670.60

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

IPOApr 17, 2012
Beta2.28
ATR, 14d0.32
Rel volume0.90
Short float0.45%
Insider own0.84%
Inst own1.03%

Snapshot

6 groups

Valuation

Index-
Market Cap25.57M
Enterprise Value-21.42M
Income-53.59M
Sales10.03M
Book/sh5.79
Cash/sh6.47
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOApr 17, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S2.55
P/B0.60
P/C0.54
P/FCF-
EV/EBITDA-
EV/Sales-2.14
Quick Ratio5.69
Current Ratio5.69
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-7.28
EPS next Y-1.63
EPS next Q-1.45
EPS this Y75.42%
EPS next Y14.31%
EPS next 5Y41.66%
EPS past 3/5Y-7.01% 0.02%
Sales past 3/5Y- -
EPS Y/Y TTM-33.93%
Sales Y/Y TTM-
EPS Q/Q3.43%
Sales Q/Q-
EarningsAug 30 AMC
EPS/Sales Surpr.-548.84% -15.17%

Ownership

Insider Own0.84%
Insider Trans0.00%
Inst Own1.03%
Inst Trans-95.77%
ROA-66.76%
ROE-78.38%
ROIC-124.19%
Gross Margin85.21%
Oper. Margin-586.33%
Profit Margin-534.13%
SMA208.06%
SMA50-23.88%
SMA200-76.60%
Trades-

Technical

Shs Outstand7.37M
Shs Float7.31M
Short Float0.45%
Short Ratio1.68
Short Interest0.03M
52W High70.60 -95.08%
52W Low2.66 30.45%
Volatility12.63% 8.23%
ATR (14)0.32
RSI (14)46.39
Beta2.28
Rel Volume0.90
Avg Volume19.75K
Volume4,455

Performance

Perf Week17.63%
Perf Month-2.80%
Perf Quarter-57.00%
Perf Half Y-62.60%
Perf YTD-93.93%
Perf Year-90.25%
Perf 3Y-90.25%
Perf 5Y-95.64%
Perf 10Y-93.64%
Recom1.75
Target Price19.66
Prev Close3.46
Price3.47
Change %0.29%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Mar 13, 2026DowngradeRRobert W. BairdOutperform → Neutral$1-71.2%
Mar 13, 2026DowngradeMMaxim GroupBuy → Hold
Mar 13, 2026DowngradeCCitizensMkt Outperform → Mkt Perform
Feb 17, 2026InitiatedCCitizensMkt Outperform$6+72.9%
May 17, 2024InitiatedCCapitalOneOverweight$10+188.2%
Aug 03, 2023InitiatedRRobert W. BairdOutperform$7+101.7%
Aug 03, 2021InitiatedLLadenburg ThalmannBuy$8.30+139.2%
Jul 16, 2021ResumedMMaxim GroupBuy$8+130.5%
Sep 28, 2018InitiatedBB. Riley FBRBuy$7.75+123.3%
Feb 15, 2018ReiteratedMMaxim GroupBuy$7 → $5+44.1%

Peers

Mkt cap
TickerCompanyMkt cap
AGENAgenus Inc320.57M
CUECue Biopharma Inc140.86M
BYSIBeyondSpring Inc25.30M
CADLCandel Therapeutics Inc716.98M
CMPXCompass Therapeutics Inc148.93M
CRVSCorvus Pharmaceuticals Inc965.00M
XNCRXencor Inc2.99B
REGNRegeneron Pharmaceuticals Inc94.14B
IOVAIovance Biotherapeutics Inc3.72B
BMYBristol-Myers Squibb Co125.87B

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B

News

latest 14 of 206
  • Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies (GlobeNewswire) -8.95%
  • Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO (GlobeNewswire)
  • IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses (GlobeNewswire)
  • Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 (GlobeNewswire) -8.81%
  • Immutep Quarterly Activities Report Q1 FY27 (GlobeNewswire)
  • Loading…
  • Immutep Receives A$2.16 million French R&D Tax Incentive (GlobeNewswire) +5.40%
  • Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 (GlobeNewswire)
  • Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026 (GlobeNewswire)
  • Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research (GlobeNewswire) -5.32%
  • Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
  • Immutep Receives ~A$0.86 Million R&D Tax Incentive (GlobeNewswire)
  • Change to American Depositary Share Ratio (GlobeNewswire)
  • Immutep Outlines Focused Development Strategy for Eftilagimod Alfa ("efti") (GlobeNewswire) +14.83%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S22026-08-30-3.348-0.516-3.2849.9511.723
2026S12026-02-24-4.336-3.946-3.9975.509.402
2025S22025-08-28-3.934-3.722-3.4000.920.002
2025S12025-02-26-1.928-2.720-2.0364.550.702
2024S22024-08-29-2.430-2.508-2.3261.191.835
2024S12024-02-27-2.304-2.660-2.3152.671.851
2023S22023-08-29-2.680-2.852-2.8261.242.183
2023S12023-02-24-3.124-2.444-3.0841.740.001
2022S22022-09-16-2.166-2.988-2.6010.720.992
2022S12022-02-24-2.712-1.502-2.7682.020.152
2021S22021-11-14-1.918--2.0231.17-2
2021S12021-02-24-5.972-4.700-5.4011.791.68-
2020S22020-09-21-4.256--2.2912.99-1
2019S22019-10-15-3.908--3.9540.09-1
2019S12019-02-28-3.958-3.762-3.9302.560.00-
2018S22018-11-08-1.234--4.6301.92--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.780--4.3945.41-
2021FY-7.238-6.892-7.3122.904.09
2022FY-5.116-7.196-5.3694.631.78
2023FY-5.754-5.164-5.9603.383.81
2024FY-4.830-4.062-4.6622.602.88
2025FY-5.524-5.330-5.4663.305.30
2026FY-7.726-4.871-9.56815.1716.51
2027FY--1.899--1.90
2028FY--1.627--1.43
2029FY--1.534--5.50
2030FY--2.820---
2031FY--2.730---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027S1S2026-10-152101.431.431.43
2027S1S2026-09-203101.851.432.71
2027S1S2026-09-143111.851.432.71
2027S1S2026-09-012112.071.432.71
2027S1S2026-08-312112.071.432.71
2027S1S2026-07-212022.061.402.71
2027S1S2026-07-071012.712.712.71
2027S1S2026-06-201012.772.772.77
2027S1S2026-06-052012.091.422.77
2027S1S2026-05-112102.111.422.81
2027S1S2026-04-302202.111.422.81
2027S1S2026-03-122112.091.422.77
2027S1S2026-02-272112.701.433.97
2027S1S2026-02-252112.701.423.97

Estimate history

EPS, annual-7.356-7.887-4.394-7.312-5.369-5.96-4.662-5.466-7.303
Period201820192020202120222023202420252026
EPS, quarterly
Period
Sales, annual2.0380.15.01900.1240009.864
Period201820192020202120222023202420252026
Sales, quarterly
Period
Shares, annual1.5621.7492.4993.8354.445.9917.2637.3027.369
Period201820192020202120222023202420252026
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue10.039.860.000.000.000.120.005.020.10
Cost of Goods Sold Incl. D&A1.481.681.551.481.391.501.54--
Gross Profit8.558.19-1.55-1.48-1.39-1.37-1.54--
Selling, General and Administrative Excl. Other67.3865.0343.8231.5528.8426.4615.9917.9216.42
Research and Development-51.9432.2420.6319.3718.388.9611.9711.27
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-58.83-56.84-45.37-33.03-30.23-27.84-17.54-14.30-17.67
Interest Expense0.050.050.020.020.010.070.010.01-
Unusual Expense1.303.370.090.080.00-0.197.33-0.720.03
Net Income Before Taxes-53.59-53.74-39.79-28.00-26.84-23.36-22.30-9.03-13.12
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-53.59-53.74-39.79-28.00-26.84-23.36-22.30-9.03-13.12
Net Income From Continuing Operations-53.59-53.74-39.79-28.00-26.84-23.36-22.30-9.03-13.12
Net Income-53.59-53.74-39.79-28.00-26.84-23.36-22.30-9.03-13.12
EPS (Recurring)-7.15-6.98-5.46-4.65-5.96-5.40-5.63-4.64-7.87
EPS (Basic, Before Extraordinaries)-7.28-7.30-5.47-4.66-5.96-5.37-7.31-4.39-7.89
EPS (Diluted)-7.28-7.30-5.47-4.66-5.96-5.37-7.31-4.39-7.89
EBITDA-57.35-55.16-43.82-31.55-28.84-26.34-15.99-12.90-16.32
Non-Operating Income (Expense)6.586.515.695.143.414.352.584.564.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-1.080.751.181.350.750.910.830.79
Price To Sales Ratio6.126.22---1,429.77-8.85598.75
Gross Margin85.2183.01----1,111.18---
Operating Margin-586.33-576.21----22,528.39--284.85-17,668.06
Net Margin-534.13-544.79----18,906.54--179.90-13,123.30
Shares Outstanding7.377.377.307.265.994.443.832.501.75
Market Capitalization25.5025.504,790.085,077.824,198.873,516.935,790.701,053.281,232.84

Income statement, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S12023S22023S1
Total Revenue7.362.670.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.740.740.700.680.830.650.620.63
Gross Profit6.621.93-0.70-0.68-0.83-0.65-0.62-0.63
Selling, General and Administrative Excl. Other34.0133.3724.9918.8615.7315.8214.1214.85
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-27.40-31.43-25.69-19.54-16.56-16.47-14.75-15.48
Interest Expense0.030.010.010.010.010.010.000.01
Unusual Expense0.950.340.040.050.040.040.04-0.03
Net Income Before Taxes-24.20-29.39-24.78-14.79-14.14-13.85-13.02-13.82
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-24.20-29.39-24.78-14.79-14.14-13.85-13.02-13.82
Net Income From Continuing Operations-24.20-29.39-24.78-14.79-14.14-13.85-13.02-13.82
Net Income-24.20-29.39-24.78-14.79-14.14-13.85-13.02-13.82
EPS (Recurring)-3.19-3.96-3.40-2.03-2.32-2.31-2.82-3.09
EPS (Basic, Before Extraordinaries)-3.28-4.00-3.40-2.04-2.33-2.32-2.83-3.08
EPS (Diluted)-3.28-4.00-3.40-2.04-2.33-2.32-2.83-3.08
EBITDA-26.65-30.69-24.99-18.86-15.73-15.82-14.12-14.85
Non-Operating Income (Expense)4.182.400.964.812.472.671.771.64
Stock Option Compensation Expense--0.580.170.520.650.760.58
Price To Sales Ratio6.12157.33-----1,280.24
Gross Margin89.8972.34------
Operating Margin-372.23-1,175.70------
Net Margin-328.78-1,099.42------
Shares Outstanding7.377.377.307.287.266.005.994.51
Market Capitalization25.508,429.684,790.086,317.265,077.825,706.384,198.873,077.54

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments47.7284.99121.4782.1555.0145.4918.1211.6317.34
Short Term Receivables6.677.125.055.315.764.602.343.672.57
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.485.601.282.381.681.280.991.221.25
Total Current Assets55.8697.71127.7989.8462.4551.3721.4516.5221.16
Net Property, Plant & Equipment0.760.370.450.310.210.230.170.040.02
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets1.034.725.506.327.269.6510.4611.8913.54
Deferred Tax Assets--------2.02
Other Assets0.040.080.871.680.340.340.000.000.00
Total Assets57.69102.88134.6298.1570.2661.5832.0828.4536.74
Short Term Debt Incl. Current Port. of LT Debt0.200.860.160.120.120.160.090.000.00
Accounts Payable4.083.632.533.631.971.371.131.791.19
Income Tax Payable--------0.00
Other Current Liabilities5.533.884.322.752.322.481.101.921.65
Total Current Liabilities9.818.367.006.504.414.012.323.722.85
Long Term Debt0.520.210.910.691.071.9634.6734.4435.52
Provision for Risks Charges0.250.180.140.110.080.070.040.030.02
Deferred Tax Liabilities--------2.02
Other Liabilities4.480.000.000.000.000.540.652.222.18
Total Liabilities15.068.758.057.315.566.5837.6840.4142.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity42.6394.13126.5790.8464.6955.01-5.60-11.96-5.84
Total Shareholders Equity42.6394.13126.5790.8464.6955.01-5.60-11.96-5.84
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity42.6394.13126.5790.8464.6955.01-5.60-11.96-5.84
Total Liabilities & Stockholders Equity57.69102.88134.6298.1570.2661.5832.0828.4536.74
Book Value Per Share5.7912.8917.4315.1614.5714.34-2.24-6.84-3.74
Tangible Book Value Per Share5.6512.2516.6714.1112.9411.83-6.43-13.64-12.41
Full-Time Employees-------2419
Price to Book Ratio0.6044.7161.1255.6755.73107.91-192.8453.2055.56
Return on Assets-66.94-33.50-24.05-31.87-35.44-47.61-29.83-40.25-30.04
Return on Equity-78.59-36.05-25.75-34.51-39.03-90.26---136.14
Return on Invested Capital-124.53-42.17-21.96-29.32-35.52-39.14-31.06-58.38-33.28
Quick Ratio5.6911.6918.2513.8114.1612.819.264.447.43
Current Ratio5.6911.6918.2513.8114.1612.819.264.447.43

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income--53.74-39.79-28.00-26.84-23.36-22.30-9.03-13.12
Depreciation-1.681.551.481.391.501.541.391.34
Other Funds (Non Cash)-3.242.891.071.151.079.090.311.09
Funds from Operations-50.62-48.82-35.35-25.44-24.30-20.79-11.67-7.33-10.69
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-11.24-4.842.620.51-1.13-1.490.06-0.25
Cash from Operating Activities-38.97-37.58-40.19-22.82-23.78-21.93-13.15-7.27-10.93
Capital Expenditures-0.07-0.06-0.18-0.61-0.06-0.02-0.01-0.01-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments39.7538.34-24.78-13.160.000.000.000.000.00
Purchase of Investments-3.51-3.39-57.50-13.160.000.000.000.000.00
Sale Or Maturity of Investments43.2741.7332.720.000.000.000.000.000.00
Other Uses-0.02-0.020.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities39.6738.26-24.96-13.78-0.06-0.02-0.01-0.01-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.00-0.1662.4951.2836.6639.1013.785.90
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.00-0.1662.4951.2836.6639.1013.785.90
Proceedsfrom Stock Options0.000.00-0.1662.4951.2836.6630.7013.784.14
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.040.000.000.350.00-0.17
Other Financing Activities Uses0.000.000.000.000.000.000.000.00-0.17
Cash from Financing Activities-0.15-0.15-0.3462.3851.1436.5039.2813.735.73
Exchange Rate Effect-3.17-3.064.36-0.631.91-0.49-0.560.090.29
Net Change in Cash-2.62-2.53-61.1225.1529.2114.0725.566.54-4.94
Free Cash Flow-39.03-37.65-40.21-22.84-23.84-21.94-13.17-7.28-10.96
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S1
Cash & Short Term Investments47.7266.1084.9998.61121.4770.78
Short Term Receivables6.6725.027.124.915.054.19
Inventories0.000.000.000.000.000.00
Other Current Assets1.482.095.604.071.282.15
Total Current Assets55.8693.2297.71107.59127.7977.13
Net Property, Plant & Equipment0.760.880.370.420.450.54
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.033.974.724.815.505.96
Other Assets0.040.090.080.070.870.83
Total Assets57.6998.16102.88112.89134.6284.47
Short Term Debt Incl. Current Port. of LT Debt0.200.170.860.800.160.14
Accounts Payable4.086.023.632.476.392.07
Other Current Liabilities5.5325.163.882.440.462.26
Total Current Liabilities9.8131.358.365.707.004.47
Long Term Debt0.520.630.210.240.910.96
Other Liabilities4.480.210.000.150.000.00
Total Liabilities15.0632.218.756.108.055.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity42.6365.9594.13106.79126.5778.91
Total Shareholders Equity42.6365.9594.13106.79126.5778.91
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity42.6365.9594.13106.79126.5778.91
Total Liabilities & Stockholders Equity57.6998.16102.88112.89134.6284.47
Book Value Per Share5.798.9512.8914.6717.4313.15
Tangible Book Value Per Share5.658.4112.2514.0116.6712.16
Price to Book Ratio0.6088.7444.7149.8161.1263.32
Return on Assets-66.76-51.34-33.32-29.32-24.06-37.64
Return on Equity-78.38-62.72-35.86-31.16-25.75-41.06
Return on Invested Capital-56.07-44.15-26.26-13.82-11.09-17.35
Quick Ratio5.692.9711.6918.8618.2517.24
Current Ratio5.692.9711.6918.8618.2517.24

Cash flow, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S1
Funds from Operations-31.84-18.77-15.75-18.87-13.51-12.04
Extraordinary Item----0.000.00
Cash from Operating Activities-20.19-18.77-20.49-18.87-10.88-12.04
Capital Expenditures-0.00-0.06-0.02-0.16-0.40-0.22
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments16.5523.2017.09-41.37-13.16-0.06
Purchase of Investments-0.24-3.28-11.65-44.67-13.16-0.06
Sale Or Maturity of Investments16.7926.4828.753.310.000.00
Other Uses-0.020.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities16.5223.1417.08-41.52-13.56-0.27
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.01-0.1762.95-0.19
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.01-0.1762.95-0.19
Proceedsfrom Stock Options0.000.000.01-0.1762.95-0.19
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.04-0.040.04-0.00
Other Financing Activities Uses0.000.000.04-0.040.00-0.00
Cash from Financing Activities-0.08-0.07-0.05-0.2862.92-0.28
Exchange Rate Effect-2.38-0.801.702.57-0.39-0.25
Net Change in Cash-6.123.50-1.77-58.1138.10-12.85
Free Cash Flow-20.20-18.83-20.51-18.88-10.88-12.05

Revenue breakdown

Pharmaceutical Preparations2025: 6.69M 2026: 16.38M
Australia2025: 6.69M 2026: 16.38M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.45%0.0M7.3M16.12K
2026-10-150.46%0.0M7.3M15.68K
2026-09-300.64%0.0M7.3M15.30K
2026-09-150.66%0.0M7.3M14.74K
2026-08-310.73%0.1M7.3M17.12K
2026-08-140.52%0.0M7.3M25.72K
2026-07-310.82%0.1M7.3M32.50K
2026-07-151.47%0.1M7.3M109.21K
2026-06-302.67%0.2M7.3M668.33K
2026-06-153.04%0.2M7.3M671.10K
2026-05-292.97%0.2M7.3M774.48K
2026-05-153.52%0.3M7.3M767.83K
2026-04-304.28%0.3M7.3M771.70K
2026-04-150.85%0.1M7.3M700.60K
2026-03-310.89%0.1M7.3M68.22K
2026-03-133.57%0.3M7.3M53.45K
2026-02-273.30%0.2M7.3M36.55K
2026-02-133.21%0.2M7.3M36.32K
2026-01-303.17%0.2M7.3M36.12K
2026-01-153.25%0.2M7.3M35.49K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-2320-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2026-06-30SEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-04SEC
2026-05-11UPLOADUpload SubmissionSEC
2026-05-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-05-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-24CORRESPSEC
2026-04-163Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-15SEC
2026-04-133Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-133Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-073Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-07UPLOADUpload SubmissionSEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-19SEC
2026-03-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-13SEC
2026-02-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-25SEC
2026-02-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-06SEC
2026-01-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.0.50%
Vanguard Personalized Indexing Management, LLC0.24%
MARSHALL WACE, LLP0.06%
TWO SIGMA INVESTMENTS, LP0.05%
Mariner, LLC0.05%
XTX Topco Ltd0.03%
CITIGROUP INC0.03%
HBK Sorce Advisory LLC0.03%
RHUMBLINE ADVISERS0.03%
LPL Financial LLC0.02%

Funds

Fund% owned
iShares Biotechnology ETF0.50%
Fidelity Nasdaq Composite Index Fund0.01%
Brighthouse/Dimensional International Small Company Portfolio0.01%
LVIP Dimensional International Core Equity Fund0.00%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. IMMP. Cached 15 minutes.

Some panels did not load: insider.